Page 4 - Emerging Focus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Emerging focus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Emerging Focus Today - Breaking & Trending Today

Global Non-Viral Drug Delivery Systems Market Trends and Forecasts Report 2021: Extensive Study of the Current Landscape and the Likely Opportunities in Intracellular Drug Delivery Technologies


Share this article
Share this article
ResearchAndMarkets.com s offering.
The Non-Viral Drug Delivery Systems: Focus on Intracellular Technologies and Intracellular Biologics Market, 2021-2030 report features an extensive study of the current landscape and the likely future opportunities in intracellular drug delivery technologies market for the next 10 years.
One of the key objectives of the report was to estimate the existing market size and identify potential future growth opportunities for intracellular drug delivery technologies. Based on likely licensing deal structures and agreements that are expected to be signed in the foreseen future, we have provided an informed estimate on the evolution of the market over the period 2021-2030. ....

Anders Hogset , Itay Friedman , Biond Biologics , Laura Wood , Tehila Ben Moshe , List Of Technology Developers , Technology Competitiveness Analysis , Path Holdings , Type Of Organization , Type Of Partnership , Year Of Partnership , Technology Portfolio , Company Overview , Office Hours Call , Entos Pharmaceuticals , Authority Patent Offices , Phase Of Development , E St Office Hours Call , Delivery Technology , Partnership Models , Company Snapshot , Business Development , Route Of Administration , Viral Drug Delivery Systems , Intracellular Technologies , Intracellular Biologics ,

Worldwide Antisense Oligonucleotide Therapeutics Industry to 2030 - Market Trends and Global Forecasts


Share this article
Share this article
ResearchAndMarkets.com s offering.
Since the approval of Vitravene (for the treatment of cytomegalovirus retinitis) in 1998, antisense oligonucleotide (ASO) therapies have evolved into a prominent class of therapeutics. In addition to the seven drugs, based on such molecules, that are commercially available, around 160 candidates are under development. Examples of recently approved antisense therapeutics include (in reverse chronological order) Viltepso (duchenne muscular dystrophy, March 2020), Vyondys 53 (duchenne muscular dystrophy, December 2019) and Waylivra (hereditary transthyretin-mediated (hATTR) amyloidosis, May 2019).
Given their ability to target the root cause of diseases, at the protein expression level, these disease-modifying interventions have potential applications across a wide range of therapeutic areas (including but not limited to oncological disorders, neurodegenerative disorders, respiratory disorders, a ....

United Kingdom , United States , Codiak Biosciences , Daiichi Sankyo , Alta Bioscience , Tominersen Roche , Allianz Bioinnovation , Laura Wood , Type Of Recipient Organization , Cold Spring Harbor Laboratory , Path Holdings , Agilent Technologies , Catabasis Pharmaceuticals , Prominent Program Officers , List Of Developers , Br Biochem Life Sciences , Inotersen Ionis Pharmaceuticals , Volanesorsen Ionis Pharmaceuticals , Many More Companies , Ajinomoto Bio Pharma Services , Company Overview , Office Hours Call , Dalton Pharma Services , Institute Center , Phase Of Development , E St Office Hours Call ,